Results 51 to 60 of about 28,123 (301)
P-cadherin (pCAD) and LI-cadherin (CDH17) are cell-surface proteins belonging to the cadherin superfamily that are both highly expressed in colorectal cancer.
Alyssa Synan+21 more
doaj +1 more source
Emerging new therapeutic antibody derivatives for cancer treatment
Monoclonal antibodies constitute a promising class of targeted anticancer agents that enhance natural immune system functions to suppress cancer cell activity and eliminate cancer cells.
Shijie Jin+7 more
doaj +1 more source
Brain metastases (BM) from lung cancer are aggressive with poor prognosis. This review covers clinical features, diagnosis, early metastasis, and multi‐omics‐elucidated mechanisms, especially the tumor microenvironment of lung cancer with BM. It also discusses preclinical models, signaling pathways, and emerging therapies.
Yixiang Zhu+5 more
wiley +1 more source
Bispecific antibodies represent an emerging class of antibody drugs that are commonly generated by fusion of Fv or scFv antigen binding domains to IgG or Fab scaffolds.
Pallavi Bhatta, David P. Humphreys
doaj +1 more source
Nephrotoxicity in Bispecific Antibodies Recipients: Focus on T-Cell-Engaging Bispecific Antibodies
Recently, bispecific antibodies (BsAbs) are evolving the landscape of cancer treatment and have significantly improved the outcomes of relapsed or refractory cancer patients. As increasing BsAbs entered clinical practice, specific toxicities have emerged, and renal side-effects have been described.
Wen, Xiaoli, Xu, Gaosi
openaire +2 more sources
DNA‐Based Genetic and Non‐Genetic Tools for Receptor Engineering. This review highlights recent advances in DNA‐based strategies for receptor engineering, including genetic approaches like domain fusion and site‐directed mutagenesis, as well as non‐genetic methods using functional nucleic acids, DNA nanostructures, and dynamic DNA reactions.
Hexin Nan+4 more
wiley +1 more source
Producing and prospects for the use of bispecific antibodies for the treatment of cancer
Bispecific antibody molecules contain two different antigen-binding centers. Particular interest in bispecific antibodies is due to their therapeutic application.
S. E. Sedykh, G. A. Nevinsky
doaj +1 more source
FM‐DEL1 and FM‐DEL2 are constructed by installing one or two sets of building blocks on a phenylalanine central scaffold. FM‐DELs are screened against markers of prostate, and renal cell carcinoma, and against an immunological target expressed on the surface of natural killer cells.
Francesca Migliorini+12 more
wiley +1 more source
Harnessing MerTK agonism for targeted therapeutics
Phagocytosis plays important roles both in homeostasis and under pathological conditions. Fcγ receptor-mediated phagocytosis has been exploited as an integral mechanism for antibody-based therapies.
Vivekananda Kedage+6 more
doaj +1 more source
Structural modification of clofoctol yielded a novel blood‐brain barrier‐permeable compound, B7, featuring a multi‐substituted diaryl scaffold. B7 demonstrates potent anti‐glioblastoma activity by suppressing glioblastoma stem cells proliferation, migration, and invasion through interactions with five key residues of poliovirus receptor cell adhesion ...
Yong‐jian Wang+9 more
wiley +1 more source